Log In Get Started

News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • IMF says BOJ is on the right track toward policy normalization.
  • IMF warns BOJ may need to accelerate rate increases if inflation overshoots.
  • IMF urged Japan to clarify funding sources for large spending and temporary tax cuts.
  • IMF called on Japan to publish a medium-term fiscal plan to calm markets.
  • IMF comments raise the prospect of faster BOJ tightening and higher Japanese yields.
  • IMF warned fiscal uncertainty could undermine investor confidence in Japanese assets.

Latest Articles

PREMIUM WINE AND CAVIAR COMPANY TOP WEALTH GROUP HOLDING LIMITED RELOCATES GLOBAL HEADQUARTERS FROM HONG KONG, CHINA TO LILLE, FRANCE, SIGNALING STRATEGIC PIVOT TO GLOBAL MARKETS
Sep 22, 2026
Sofia Navarro
Press Releases

PREMIUM WINE AND CAVIAR COMPANY TOP WEALTH GROUP HOLDING LIMITED RELOCATES GLOBAL HEADQUARTERS FROM HONG KONG, CHINA TO LILLE, FRANCE, SIGNALING STRATEGIC PIVOT TO GLOBAL MARKETS

Top Wealth Group Holding Limited, a NASDAQ-listed premium caviar and wine supplier, announced the relocation of its global headquarters from Hong Kong to Lille, France. This strategic move supports the company's shift from a regional Asian focus to a wider global luxury food and beverage market presence. The relocation aims to enhance distribution …

TWG
IMUNON Reports Independent Data Monitoring Committee Recommends Continued Phase 2 Development of IMNN-001 Following Favorable Safety Review
Sep 22, 2026
Marcus Reed
Press Releases

IMUNON Reports Independent Data Monitoring Committee Recommends Continued Phase 2 Development of IMNN-001 Following Favorable Safety Review

IMUNON's DNA-based immunotherapy candidate IMNN-001 demonstrated a favorable safety profile with no serious immune-related adverse events in an ongoing Phase 2 minimal residual disease (MRD) study for advanced ovarian cancer. The Independent Data Monitoring Committee recommended continuation without modifications, validating the drug's tolerability…

IMNN
Marker Therapeutics Highlights Expanded Manufacturing Support of CDMO Partner Following Formation of Kincellis Advanced Therapies
Sep 22, 2026
Derek Hwang
Press Releases

Marker Therapeutics Highlights Expanded Manufacturing Support of CDMO Partner Following Formation of Kincellis Advanced Therapies

Marker Therapeutics highlights enhanced manufacturing support for its lead immuno-oncology program MT-601 following the combination of its CDMO partner Cellipont Bioservices with Kincell Bio to form Kincellis Advanced Therapies. This expanded U.S.-based organization offers broader infrastructure and expertise to support late-stage clinical developm…

MRKR
Natural design. Amplified: Smith+Nephew announces FDA 510(k) clearance and first surgical cases of LANDMARK™ Total Knee System
Sep 22, 2026
Caleb Monroe
Press Releases

Natural design. Amplified: Smith+Nephew announces FDA 510(k) clearance and first surgical cases of LANDMARK™ Total Knee System

Smith+Nephew announced FDA 510(k) clearance for its LANDMARK Total Knee System, a next-generation knee replacement designed to replicate healthy knee anatomy and support personalized knee arthroplasty. The company has completed first surgical cases and plans a phased commercial launch starting with early adopters and broader availability in 2027.

SNN
Swvl Establishes Presence in Madinah, Launching 24/7 Shuttle Service Across Seven Hotels in the Pilgrimage Transport Segment
Sep 22, 2026
Nina Shah
Press Releases

Swvl Establishes Presence in Madinah, Launching 24/7 Shuttle Service Across Seven Hotels in the Pilgrimage Transport Segment

Swvl Holdings Corp announces the launch of a 24/7 shuttle service in Madinah, Saudi Arabia, connecting seven hotels to Al-Masjid an-Nabawi and key city landmarks. This initiative deepens Swvl's presence in the Kingdom of Saudi Arabia, targeting the high-demand pilgrimage transport segment with technology-enabled mass mobility solutions. The move al…

SWVL
Adagene Announces NMPA Clearance of Investigational New Drug Application for ADG138, a Novel HER2xCD3 Double-Masked Bispecific T-Cell Engager
Sep 22, 2026
Derek Hwang
Press Releases

Adagene Announces NMPA Clearance of Investigational New Drug Application for ADG138, a Novel HER2xCD3 Double-Masked Bispecific T-Cell Engager

Adagene announced that China's National Medical Products Administration (NMPA) has approved its IND application for ADG138, a novel double-masked HER2xCD3 bispecific T-cell engager designed with proprietary SAFEbody technology to selectively target HER2-expressing tumors with reduced systemic toxicity. The company plans to initiate a Phase 1 study …

ADAG
Clene to Present at Upcoming Investor Conferences
Sep 22, 2026
Derek Hwang
Press Releases

Clene to Present at Upcoming Investor Conferences

Clene Inc., a late-stage biopharmaceutical company focused on mitochondrial health therapies for neurodegenerative diseases, announced its participation in the 5th Annual ROTH Healthcare Opportunities Conference and the Lytham Partners Investor Conference Fall Event on September 29-30, 2026. Management will conduct one-on-one investor meetings and …

CLNN
Rhythm Pharmaceuticals Announces Health Canada Approval of IMCIVREE® (setmelanotide) for Weight Management in Adult and Pediatric Patients 4 years of Age and Older with Acquired Hypothalamic Obesity
Sep 22, 2026
Caleb Monroe
Press Releases

Rhythm Pharmaceuticals Announces Health Canada Approval of IMCIVREE® (setmelanotide) for Weight Management in Adult and Pediatric Patients 4 years of Age and Older with Acquired Hypothalamic Obesity

Rhythm Pharmaceuticals announced Health Canada’s approval of IMCIVREE® (setmelanotide) for managing weight in adult and pediatric patients aged 4 and older with acquired hypothalamic obesity (HO). This indication expansion follows successful Phase 3 trial results showing significant BMI reduction. IMCIVREE is a first-in-class MC4R agonist targeting…

RYTM
EagleNXT Provides Update on American-Made Drone and Sensor Shipments from U.S. Headquarters in Allen, Texas
Sep 22, 2026
Sofia Navarro
Press Releases

EagleNXT Provides Update on American-Made Drone and Sensor Shipments from U.S. Headquarters in Allen, Texas

AgEagle Aerial Systems Inc., trading as EagleNXT (NYSE: UAVS), announced that its Allen, Texas headquarters is now shipping domestically-produced eBee VISION ISR drones and the newly released MicaSense RedEdge-MX multispectral sensors. The company recently fulfilled a key order delivering nine eBee VISION kits to the U.S. Army's National Training C…

UAVS
Genius Group to host Genius Future Summit on November 5-6, 2026.
Sep 22, 2026
Marcus Reed
Press Releases

Genius Group to host Genius Future Summit on November 5-6, 2026.

Genius Group Limited (NYSE American: GNS) is hosting its second annual Genius Future Summit on November 5-6, 2026, at Genius City in Bali. The event will showcase leading futurists like Dr. Michio Kaku and Peter Diamandis, discuss key future trends in AI, blockchain, and community, and launch new projects including the Genius Awards and Genius City…

GNS
Lianhe Sowell International Group Ltd. Signs Strategic Cooperation Agreement with Subsidiary of Chery Group Holding Company to Advance Intelligent Equipment in China’s Automotive Aftermarket
Sep 22, 2026
Maya Rios
Press Releases

Lianhe Sowell International Group Ltd. Signs Strategic Cooperation Agreement with Subsidiary of Chery Group Holding Company to Advance Intelligent Equipment in China’s Automotive Aftermarket

Lianhe Sowell International Group Ltd., a Nasdaq-listed provider of industrial machine vision and automation solutions, has signed a strategic cooperation agreement with Kumquat Technology Co., a Chery Group subsidiary operating 1,000 4S stores across China. This partnership aims to promote intelligent equipment solutions for 24 automotive aftermar…

LHSW
Lantheus Receives Final FDA Approval for BRAVNETSA™ (Lutetium Lu 177 Dotatate), the Only Radiopharmaceutical FDA has Determined to be Bioequivalent and Therapeutically Equivalent to LUTATHERA® for the Treatment of GEP-NETs
Sep 22, 2026
Jordan Park
Press Releases

Lantheus Receives Final FDA Approval for BRAVNETSA™ (Lutetium Lu 177 Dotatate), the Only Radiopharmaceutical FDA has Determined to be Bioequivalent and Therapeutically Equivalent to LUTATHERA® for the Treatment of GEP-NETs

Lantheus Holdings, Inc. announced that the FDA has granted final approval for BRAVNETSA™ (lutetium Lu 177 dotatate), establishing it as the only radiopharmaceutical deemed bioequivalent and therapeutically equivalent to LUTATHERA® for treating somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Approval via the A…

LNTH
Host Digital Debuts on NYSE American as HOST and Exercises its Right to Acquire a Second Site from its Sponsor for its AI Data Center Platform
Sep 22, 2026
Ajmal Hussain
Press Releases

Host Digital Debuts on NYSE American as HOST and Exercises its Right to Acquire a Second Site from its Sponsor for its AI Data Center Platform

Host Digital Inc., a U.S.-based digital infrastructure company specializing in AI and high-performance computing data centers, has begun trading on the NYSE American under ticker HOST. The company completed a merger to acquire its initial Site I data center and signed an agreement granting preferential rights to acquire additional sites from its Sp…

HOST
Filana Therapeutics Announces FDA Lift of Clinical Hold on Simufilam, Enabling Phase 2a Study in TSC-Related Epilepsy
Sep 22, 2026
Hana Yamamoto
Press Releases

Filana Therapeutics Announces FDA Lift of Clinical Hold on Simufilam, Enabling Phase 2a Study in TSC-Related Epilepsy

Filana Therapeutics announced the FDA has lifted the clinical hold on simufilam, allowing the company to proceed with a Phase 2a study targeting Tuberous Sclerosis Complex-related epilepsy. Patient screening is expected to begin in early 2027. The 16-week trial will assess safety, tolerability, and efficacy in seizure reduction in 40 patients, supp…

FLNA